Interim Report for the period October – December 2023

Leqembi launched in Japan and approved in China Events during the fourth quarter 2023 · Leqembi was launched in Japan on December 20 which meant that the country was the second market in the world after the USA where the drug is available · Data presented at the CTAD congress further supported Leqembi’s disease modifying characteristics and safety profile as well as the subcutaneous formulation · BioArctic and Eisai have agreed on commercialization and co-promotion for the Nordic countries Events after the end of the period · The European Medicines Agency (EMA)